phrykt

Cytek Biosciences, Inc. (CTKB): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of CTKB were reported in the last 12 months. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Cytek Biosciences

From the latest filings

Overall: about as much buying as selling. Famous investors mostly sold. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns CTKB

154 funds and institutions reported CTKB shares worth $366M at the end of Q2 2026, about 64% of the company. The largest holder is BlackRock, Inc. with 7.4%.

Funds and institutions (13F) 64%Everyone else 36%

10 largest owners, by share of the company

BlackRock, Inc.7.4%
Millennium Management LLC7.2%
Boston Partners5.9%
Hhlr Advisors, Ltd.5.2%
Topline Capital Management, LLC4.9%
Vanguard Capital Management LLC3.8%
Geode Capital Management, LLC2.4%
Dimensional Fund Advisors LP2.0%
State Street Corp2.0%
Goldman Sachs Group Inc1.7%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.9.58M7.42%$42.4M-44%
Millennium Management LLC9.34M7.23%$41.4M+48%
Boston Partners7.66M5.93%$33.9M+32%
Hhlr Advisors, Ltd.6.66M5.15%$29.5MNo change
Topline Capital Management, LLC6.28M4.87%$27.8M-11%
Vanguard Capital Management LLC4.94M3.82%$21.9M+4%
Geode Capital Management, LLC3.06M2.37%$13.6M+8%
Dimensional Fund Advisors LP2.62M2.03%$11.6M-2%
State Street Corp2.57M1.99%$11.4M-38%
Goldman Sachs Group Inc2.17M1.68%$9.6M-8%
Royce & Associates LP2.08M1.61%$9.2M+27%
Russell Investments Group, Ltd.1.51M1.17%$6.7M+11%
Acadian Asset Management LLC1.38M1.07%$6.1M+245%
Bank of America Corp1.32M1.02%$5.8M+30%
Vanguard Portfolio Management LLC1.14M0.88%$5.1M-51%
Charles Schwab Investment Management Inc1.07M0.83%$4.8M-3%
Sixth Street Partners Management Company, L.P.1.07M0.83%$4.8M–
Northern Trust Corp1.00M0.78%$4.4M-0%
Hrt Financial LP997,7690.77%$4.4M+141%
Arrowstreet Capital, Limited Partnership973,8330.75%$4.3M+204%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No CTKB insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

CTKB short interest

Low short interest. 3.2% of CTKB shares are sold short: about 1 share in 32. Over the last 12 reports the number of shares short went down 40%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 4.11M CTKB shares were sold short, 3.2% of the shares outstanding, down 6.9% from the report before. At the average daily volume of 1.15M shares, buying them all back would take about 3.6 trading days (days to cover).

Shares short, % of all shares

3.16%May 15Oct 306.10%

Days to cover

3.6May 15Oct 309.2

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20264.11M3.16%-7%1.15M3.6
Oct 15, 20264.41M3.39%-15%1.64M2.7
Sep 30, 20265.22M4.01%-1%1.67M3.1
Sep 15, 20265.24M4.03%+6%913,6725.7
Aug 31, 20264.93M3.79%-1%743,0736.6
Aug 14, 20264.99M3.84%+2%982,4045.1
Jul 31, 20264.90M3.77%-3%656,4227.5
Jul 15, 20265.03M3.89%+43%921,1625.5
Jun 30, 20263.51M2.72%-50%3.39M1.0
Jun 15, 20267.04M5.45%-4%1.27M5.5
May 29, 20267.30M5.66%+6%896,9598.1
May 15, 20266.86M5.32%-11%1.15M6.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Cytek Biosciences company events

Cytek Biosciences filed 11 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 4, 2026.

  1. Nov 4, 2026ResultsReleased financial results. Filing
  2. Sep 29, 2026RulesChanged its bylaws or articles. Filing
  3. Aug 24, 2026AnnouncementThe Company announced that a jury in the United States District Court for the District of Delaware returned a verdict in the patent infringement action brought by Beckman Coulter, Inc. The jury found in the Company’s favor on three of the four asserted patent claims, finding noninfringement and… Filing
  4. Aug 5, 2026ResultsReleased financial results. Filing
  5. Jul 15, 2026LeadershipAs previously disclosed, Valerie Barnett’s position as Chief Legal Officer and Corporate Secretary of Cytek Biosciences, Inc. terminated on June 29, 2026. Filing
  6. Jun 25, 2026LeadershipValerie Barnett and Cytek Biosciences, Inc. agreed that Ms. Barnett’s position as Chief Legal Officer and Corporate Secretary of the Company would terminate effective as of June 29, 2026. Filing
  7. Jun 16, 2026VoteReported shareholder vote results. Filing
  8. Jun 2, 2026LeadershipPhilippe Busque, Ph.D. submitted his resignation from his position as the Senior Vice President, Global Sales and Services of Cytek Biosciences, Inc., effective as of June 5, 2026, to pursue another career opportunity. Filing
  9. May 7, 2026ResultsReleased financial results. Filing
  10. Feb 26, 2026ResultsReleased financial results. Filing
  11. Jan 13, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Cytek Biosciences financials

Famous investors that hold CTKB

5 of the 50 well-known investors we track reported holding CTKB in their latest 13F filing. The largest position is Israel Englander's, worth $43.4M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20267.28M$43.4M0.0%-22%
Paul Tudor Jones · Tudor Investment CorpQ3 20261.01M$6M0.0%+21%
Ken Griffin · Citadel AdvisorsQ3 2026915,415$5.5M0.0%+27%
Jim Simons · Renaissance TechnologiesQ3 2026626,800$3.7M0.0%-5%
Steve Cohen · Point72 Asset ManagementQ3 202622,593$135K0.0%-95%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named CTKB in the last 120 days.

FiledHolderFormStake
Nov 13, 2026Boston Partners13G/A6.2%
Nov 13, 2026Boston Partners13G/A6.2%
Nov 3, 2026Integrated Core Strategies (US) LLC13G/A4.5%
Nov 3, 2026Integrated Core Strategies (US) LLC13G/A4.5%

Questions about Cytek Biosciences, Inc. (CTKB) stock

Who owns the most CTKB stock?

The largest reported owner of Cytek Biosciences, Inc. (CTKB) is BlackRock, Inc., with 7.4% of the company. In total, 154 funds and institutions reported holding CTKB at the end of Q2 2026, together about 64% of the shares. See the largest owners.

Are CTKB insiders buying or selling?

No CTKB insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in CTKB?

As of Oct 30, 2026, 4.11M CTKB shares were sold short, 3.2% of the shares outstanding, down 6.9% from the report before. At the average daily volume of 1.15M shares, buying them all back would take about 3.6 trading days (days to cover). See the history.

Which famous investors hold CTKB?

5 of the 50 well-known investors we track reported CTKB in their latest 13F filing, including Israel Englander, Paul Tudor Jones, Ken Griffin. The largest position is worth $43.4M. See all holders.

Executive pay

Cytek Biosciences's chief executive was paid a total of $5.1M for the year ended Dec 31, 2025, down 16% from $6.1M the year before. In the last 12 months, Cytek Biosciences's executives and directors bought no stock on the open market and sold none.

Chief executive, total pay$5.1MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$3.6MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.8MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.